Chinese PE Multimodality Imaging Artificial Intelligence Study
The CHinese pulmOnary Embolism Multimodality Imaging-artifiCial intelligencE Study (CHOICE) is a prospective observational multi-center study that will collect imaging text data and raw data of patients with pulmonary embolism (PE) in China. By combining artificial intelligence technology, it aims to identify imaging markers to assist in early diagnosis, differential diagnosis, risk stratification, and prognosis assessment of PE.
Conditions studied
Pulmonary Embolism, Chronic Thromboembolic Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Disease
About this study
The CHinese pulmOnary Embolism Multimodality Imaging-artifiCial intelligencE Study (CHOICE) is a prospective observational multi-center study that will collect imaging text data and raw data of patients with pulmonary embolism (PE) in China. By combining artificial intelligence technology, it aims to identify imaging markers to assist in early diagnosis, differential diagnosis, risk stratification, and prognosis assessment of PE.
Interventions
- Device: Artificial Intelligence — AI technology will provide novel imaging markers and generate a radiology report with relevant key slice imaging and evaluation results
Primary outcomes
- Diagnostic rate of PE (2 years)
- APE risk stratification rates (low, intermediate low, intermediate high and high risk) (2 years)
- Disease severity of chronic thromboembolic pulmonary disease (CTEPD)/chronic thromboembolic pulmonary hypertension (CTEPH) (2 years)
- 30 day mortality (2 years)
Eligibility information
Study locations
- China-Japan Frendship hospital, Beijing, 100029 China
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-03.